Navigation Links
Generex Augments Cash Position With Sales of Non-Essential Assets
Date:9/6/2011

WORCESTER, Mass. and TORONTO, Sept. 6, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that, as part of the Company's reorganization plan and following a comprehensive internal review of Company operations and a concomitant needs assessment, the Company has completed the sales of two non-essential commercial real estate properties for aggregate net cash proceeds of just over $1,000,000.  The tenanted properties were not occupied by the Company nor otherwise utilized in Company operations.

"The new Generex management team has been working to optimize and focus the Company's operations and the disposition of these assets is part of those efforts," said Mark Fletcher, the Company's President & Chief Executive Officer.  "The fair market value monetization of this real estate has augmented the Generex cash position and will permit management to concentrate on our core drug development business."

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii pro
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalyst™ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... 25, 2015 Optimal Research, LLC has been ... (ViE) Award "Best Clinical Site or Trial Network". ... has been selected as a nominee in this ViE ... "Highly Recommended" distinction in 2014. The ViE awards were ... accomplishments, and positive contributions of companies and individuals in ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 /PRNewswire/ ... has commenced Factual Stock Report coverage on ... Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty ... subsidiaries of cultivating, licensing and marketing proprietary ingredients, ... medicinal markets in North America ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... ... 2, 2009. , ... Portland, Maine (PRWEB) June 26, 2009 -- IntertechPira, in conjunction with the National Hydrogen ... conference bringing together hydrogen producers, developers and users to discuss the future of this ...
... , , , , NORCROSS, Ga., ... in providing automated instrument-reagent systems to the blood transfusion industry, ... an administrative action based on an early January 2009 inspection, ... license with respect to its Reagent Red Blood Cells and ...
... Clavis Pharma ASA (OSE:,CLAVIS) today announced that the Company ... gross proceeds through a private placement,of 10,750,000 new shares, each ... of NOK,12.00 per share (the "Private Placement"). , ... process and was,managed by Carnegie ASA and DnB NOR Markets ...
Cached Biology Technology:Industry Leaders Will Gather to Discuss the Future of the "Hydrogen Economy" in Washington DC 2Immucor Responds To FDA Notice 2Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 2Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 3Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 4Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 5
(Date:3/18/2015)... CORAL SPRINGS, Florida , March 18, 2015 ... as well as businesses, new revolutionary smart wallets and apps ... rapid pace.  Companies currently entrenched in the mobile payment industry ... ), Alibaba Group Holding Ltd. (NYSE: BABA ), ... GOOG ) and Facebook Inc. (NASDAQ: ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... 12, 2015 WHEN:Tuesday, March 17, 2015 at ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan Measurement ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must plan ... several different markets and industries. This is especially ... uptrend. Join Frost & Sullivan,s ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... developer and manufacturer of advanced molecular sensing and imaging ... that it has signed exclusive distribution deals for both ... markets covered include Australia, New Zealand, The Netherlands, ... Greece, Turkey, and Russia. The values of the ...
... for U.S. Department of Agriculture,s (USDA) Center for Veterinary Biologics ... each batch of a vaccine, the CVB has informed PETA ... with modern non-animal methods. The USDA has amended its Web ... CVB to follow the lead of Europe in adopting an ...
... newswire / - ERGONEX Pharma received one of the ... occasion of Frost & Sullivan,s ,2009 Excellence in Healthcare ... The highly competitive award was presented to ERGONEX Pharma ... impressive display of technological know-how and targeted vision. , ...
Cached Biology News:Spectros Signs New International Distribution Deals 2ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009 2
... The dsRNA Marker consists of ten double-stranded ... 300, 400, 500 and 1,000 base pairs. ... marker for determinating sizes of double-stranded RNAs. ... the dsRNA Marker is adjusted to approximately ...
... White to off-white solid. A ... and blocks the formation of N-glycosidic ... against Gram-positive bacteria, yeasts, fungi, ... functional thrombin receptors on human T-lymphoblastoid ...
... enzymes involved in matrix degradation. Of the ... exist in soluble form whereas MT-MMPs exist ... also known as MMP14, MMP15, MMP16 respectively ... to the cell surface. They have an ...
...
Biology Products: